Global and United States Genetic Obesity Drug Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Obesity, a condition in which body fat levels are elevated to extreme extent, is a common disorder. Obesity is a condition caused by the lower levels of the metabolism rate.The current advancement in Genetic Obesity Drugs in rapidly recovering the appetite inhibiting hormone level in the body is anticipated to increase the adoption of Genetic obesity drugs in physicians.

Market Analysis and Insights: Global and United States Genetic Obesity Drug Market

This report focuses on global and United States Genetic Obesity Drug market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Genetic Obesity Drug market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Drug Type, Sibutramine accounting for % of the Genetic Obesity Drug global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospitals Pharmacy was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Genetic Obesity Drug market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Genetic Obesity Drug Scope and Market Size
Genetic Obesity Drug market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Genetic Obesity Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Genetic Obesity Drug market size by players, by Drug Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Drug Type
    Sibutramine
    Orlistat
    Sympathomimetic Drugs
    Receptors Antagonists
    Others

Segment by Application
    Hospitals Pharmacy
    Retail Pharmacy
    Online Pharmacy
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Pfizer, Inc.
    Sanofi.
    Tonghua Dongbao Pharmaceutical Co., Ltd.
    Biocon.
    Adocia
    GlaxoSmithKline Plc.
    Novo Nordisk A/S.
    Oramed Pharmaceuticals, Inc
    Wockhardt.
    Eli Lilly and Company.
    Merck & Co., Inc.
    Julphar.
    Bristol-Myers Squibb Company.

 1 Study Coverage
    1.1 Genetic Obesity Drug Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Genetic Obesity Drug Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Genetic Obesity Drug Market Size for the Year 2017-2028
        1.2.2 Global Genetic Obesity Drug Market Size for the Year 2017-2028
    1.3 Genetic Obesity Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Genetic Obesity Drug in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Genetic Obesity Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Genetic Obesity Drug Market Dynamics
        1.4.1 Genetic Obesity Drug Industry Trends
        1.4.2 Genetic Obesity Drug Market Drivers
        1.4.3 Genetic Obesity Drug Market Challenges
        1.4.4 Genetic Obesity Drug Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Genetic Obesity Drug by Drug Type
    2.1 Genetic Obesity Drug Market Segment by Drug Type
        2.1.1 Sibutramine
        2.1.2 Orlistat
        2.1.3 Sympathomimetic Drugs
        2.1.4 Receptors Antagonists
        2.1.5 Others
    2.2 Global Genetic Obesity Drug Market Size by Drug Type (2017, 2022 & 2028)
    2.3 Global Genetic Obesity Drug Market Size by Drug Type (2017-2028)
    2.4 United States Genetic Obesity Drug Market Size by Drug Type (2017, 2022 & 2028)
    2.5 United States Genetic Obesity Drug Market Size by Drug Type (2017-2028)

 3 Genetic Obesity Drug by Application
    3.1 Genetic Obesity Drug Market Segment by Application
        3.1.1 Hospitals Pharmacy
        3.1.2 Retail Pharmacy
        3.1.3 Online Pharmacy
        3.1.4 Others
    3.2 Global Genetic Obesity Drug Market Size by Application (2017, 2022 & 2028)
    3.3 Global Genetic Obesity Drug Market Size by Application (2017-2028)
    3.4 United States Genetic Obesity Drug Market Size by Application (2017, 2022 & 2028)
    3.5 United States Genetic Obesity Drug Market Size by Application (2017-2028)

 4 Global Genetic Obesity Drug Competitor Landscape by Company
    4.1 Global Genetic Obesity Drug Market Size by Company
        4.1.1 Top Global Genetic Obesity Drug Companies Ranked by Revenue (2021)
        4.1.2 Global Genetic Obesity Drug Revenue by Player (2017-2022)
    4.2 Global Genetic Obesity Drug Concentration Ratio (CR)
        4.2.1 Genetic Obesity Drug Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Genetic Obesity Drug in 2021
        4.2.3 Global Genetic Obesity Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Genetic Obesity Drug Headquarters, Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Genetic Obesity Drug Headquarters and Area Served
        4.3.2 Global Genetic Obesity Drug Companies Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Genetic Obesity Drug Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Genetic Obesity Drug Market Size by Company
        4.5.1 Top Genetic Obesity Drug Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Genetic Obesity Drug Revenue by Players (2020, 2021 & 2022)

 5 Global Genetic Obesity Drug Market Size by Region
    5.1 Global Genetic Obesity Drug Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Genetic Obesity Drug Market Size by Region (2017-2028)
        5.2.1 Global Genetic Obesity Drug Market Size by Region: 2017-2022
        5.2.2 Global Genetic Obesity Drug Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Genetic Obesity Drug Market Size YoY Growth 2017-2028
        6.1.2 North America Genetic Obesity Drug Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Genetic Obesity Drug Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Genetic Obesity Drug Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Genetic Obesity Drug Market Size YoY Growth 2017-2028
        6.3.2 Europe Genetic Obesity Drug Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Genetic Obesity Drug Market Size YoY Growth 2017-2028
        6.4.2 Latin America Genetic Obesity Drug Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Genetic Obesity Drug Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Genetic Obesity Drug Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Pfizer, Inc.
        7.1.1 Pfizer, Inc. Company Details
        7.1.2 Pfizer, Inc. Business Overview
        7.1.3 Pfizer, Inc. Genetic Obesity Drug Introduction
        7.1.4 Pfizer, Inc. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.1.5 Pfizer, Inc. Recent Development
    7.2 Sanofi.
        7.2.1 Sanofi. Company Details
        7.2.2 Sanofi. Business Overview
        7.2.3 Sanofi. Genetic Obesity Drug Introduction
        7.2.4 Sanofi. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.2.5 Sanofi. Recent Development
    7.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
        7.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Company Details
        7.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Business Overview
        7.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Introduction
        7.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Development
    7.4 Biocon.
        7.4.1 Biocon. Company Details
        7.4.2 Biocon. Business Overview
        7.4.3 Biocon. Genetic Obesity Drug Introduction
        7.4.4 Biocon. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.4.5 Biocon. Recent Development
    7.5 Adocia
        7.5.1 Adocia Company Details
        7.5.2 Adocia Business Overview
        7.5.3 Adocia Genetic Obesity Drug Introduction
        7.5.4 Adocia Revenue in Genetic Obesity Drug Business (2017-2022)
        7.5.5 Adocia Recent Development
    7.6 GlaxoSmithKline Plc.
        7.6.1 GlaxoSmithKline Plc. Company Details
        7.6.2 GlaxoSmithKline Plc. Business Overview
        7.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Introduction
        7.6.4 GlaxoSmithKline Plc. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.6.5 GlaxoSmithKline Plc. Recent Development
    7.7 Novo Nordisk A/S.
        7.7.1 Novo Nordisk A/S. Company Details
        7.7.2 Novo Nordisk A/S. Business Overview
        7.7.3 Novo Nordisk A/S. Genetic Obesity Drug Introduction
        7.7.4 Novo Nordisk A/S. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.7.5 Novo Nordisk A/S. Recent Development
    7.8 Oramed Pharmaceuticals, Inc
        7.8.1 Oramed Pharmaceuticals, Inc Company Details
        7.8.2 Oramed Pharmaceuticals, Inc Business Overview
        7.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Introduction
        7.8.4 Oramed Pharmaceuticals, Inc Revenue in Genetic Obesity Drug Business (2017-2022)
        7.8.5 Oramed Pharmaceuticals, Inc Recent Development
    7.9 Wockhardt.
        7.9.1 Wockhardt. Company Details
        7.9.2 Wockhardt. Business Overview
        7.9.3 Wockhardt. Genetic Obesity Drug Introduction
        7.9.4 Wockhardt. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.9.5 Wockhardt. Recent Development
    7.10 Eli Lilly and Company.
        7.10.1 Eli Lilly and Company. Company Details
        7.10.2 Eli Lilly and Company. Business Overview
        7.10.3 Eli Lilly and Company. Genetic Obesity Drug Introduction
        7.10.4 Eli Lilly and Company. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.10.5 Eli Lilly and Company. Recent Development
    7.11 Merck & Co., Inc.
        7.11.1 Merck & Co., Inc. Company Details
        7.11.2 Merck & Co., Inc. Business Overview
        7.11.3 Merck & Co., Inc. Genetic Obesity Drug Introduction
        7.11.4 Merck & Co., Inc. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.11.5 Merck & Co., Inc. Recent Development
    7.12 Julphar.
        7.12.1 Julphar. Company Details
        7.12.2 Julphar. Business Overview
        7.12.3 Julphar. Genetic Obesity Drug Introduction
        7.12.4 Julphar. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.12.5 Julphar. Recent Development
    7.13 Bristol-Myers Squibb Company.
        7.13.1 Bristol-Myers Squibb Company. Company Details
        7.13.2 Bristol-Myers Squibb Company. Business Overview
        7.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Introduction
        7.13.4 Bristol-Myers Squibb Company. Revenue in Genetic Obesity Drug Business (2017-2022)
        7.13.5 Bristol-Myers Squibb Company. Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Genetic Obesity Drug Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Genetic Obesity Drug Market Trends
    Table 3. Genetic Obesity Drug Market Drivers
    Table 4. Genetic Obesity Drug Market Challenges
    Table 5. Genetic Obesity Drug Market Restraints
    Table 6. Global Genetic Obesity Drug Market Size by Drug Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Genetic Obesity Drug Market Size by Drug Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Genetic Obesity Drug Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Genetic Obesity Drug Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Genetic Obesity Drug Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Genetic Obesity Drug Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Genetic Obesity Drug Revenue Share by Player, 2017-2022
    Table 13. Global Genetic Obesity Drug Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Genetic Obesity Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Obesity Drug as of 2021)
    Table 15. Top Players of Genetic Obesity Drug in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Genetic Obesity Drug Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Genetic Obesity Drug Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Genetic Obesity Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Genetic Obesity Drug Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Genetic Obesity Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Genetic Obesity Drug Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Genetic Obesity Drug Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Genetic Obesity Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Genetic Obesity Drug Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Genetic Obesity Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Genetic Obesity Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Genetic Obesity Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Pfizer, Inc. Company Details
    Table 31. Pfizer, Inc. Business Overview
    Table 32. Pfizer, Inc. Genetic Obesity Drug Product
    Table 33. Pfizer, Inc. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 34. Pfizer, Inc. Recent Development
    Table 35. Sanofi. Company Details
    Table 36. Sanofi. Business Overview
    Table 37. Sanofi. Genetic Obesity Drug Product
    Table 38. Sanofi. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 39. Sanofi. Recent Development
    Table 40. Tonghua Dongbao Pharmaceutical Co., Ltd. Company Details
    Table 41. Tonghua Dongbao Pharmaceutical Co., Ltd. Business Overview
    Table 42. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product
    Table 43. Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 44. Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Development
    Table 45. Biocon. Company Details
    Table 46. Biocon. Business Overview
    Table 47. Biocon. Genetic Obesity Drug Product
    Table 48. Biocon. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 49. Biocon. Recent Development
    Table 50. Adocia Company Details
    Table 51. Adocia Business Overview
    Table 52. Adocia Genetic Obesity Drug Product
    Table 53. Adocia Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 54. Adocia Recent Development
    Table 55. GlaxoSmithKline Plc. Company Details
    Table 56. GlaxoSmithKline Plc. Business Overview
    Table 57. GlaxoSmithKline Plc. Genetic Obesity Drug Product
    Table 58. GlaxoSmithKline Plc. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 59. GlaxoSmithKline Plc. Recent Development
    Table 60. Novo Nordisk A/S. Company Details
    Table 61. Novo Nordisk A/S. Business Overview
    Table 62. Novo Nordisk A/S. Genetic Obesity Drug Product
    Table 63. Novo Nordisk A/S. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 64. Novo Nordisk A/S. Recent Development
    Table 65. Oramed Pharmaceuticals, Inc Company Details
    Table 66. Oramed Pharmaceuticals, Inc Business Overview
    Table 67. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product
    Table 68. Oramed Pharmaceuticals, Inc Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 69. Oramed Pharmaceuticals, Inc Recent Development
    Table 70. Wockhardt. Company Details
    Table 71. Wockhardt. Business Overview
    Table 72. Wockhardt. Genetic Obesity Drug Product
    Table 73. Wockhardt. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 74. Wockhardt. Recent Development
    Table 75. Eli Lilly and Company. Company Details
    Table 76. Eli Lilly and Company. Business Overview
    Table 77. Eli Lilly and Company. Genetic Obesity Drug Product
    Table 78. Eli Lilly and Company. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 79. Eli Lilly and Company. Recent Development
    Table 80. Merck & Co., Inc. Company Details
    Table 81. Merck & Co., Inc. Business Overview
    Table 82. Merck & Co., Inc. Genetic Obesity Drug Product
    Table 83. Merck & Co., Inc. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 84. Merck & Co., Inc. Recent Development
    Table 85. Julphar. Company Details
    Table 86. Julphar. Business Overview
    Table 87. Julphar. Genetic Obesity Drug Product
    Table 88. Julphar. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 89. Julphar. Recent Development
    Table 90. Bristol-Myers Squibb Company. Company Details
    Table 91. Bristol-Myers Squibb Company. Business Overview
    Table 92. Bristol-Myers Squibb Company. Genetic Obesity Drug Product
    Table 93. Bristol-Myers Squibb Company. Revenue in Genetic Obesity Drug Business (2017-2022) & (US$ Million)
    Table 94. Bristol-Myers Squibb Company. Recent Development
    Table 95. Research Programs/Design for This Report
    Table 96. Key Data Information from Secondary Sources
    Table 97. Key Data Information from Primary Sources
List of Figures
    Figure 1. Genetic Obesity Drug Product Picture
    Figure 2. Global Genetic Obesity Drug Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Genetic Obesity Drug Market Size 2017-2028 (US$ Million)
    Figure 4. United States Genetic Obesity Drug Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Genetic Obesity Drug Market Size 2017-2028 (US$ Million)
    Figure 6. United States Genetic Obesity Drug Market Share in Global 2017-2028
    Figure 7. Genetic Obesity Drug Report Years Considered
    Figure 8. Product Picture of Sibutramine
    Figure 9. Product Picture of Orlistat
    Figure 10. Product Picture of Sympathomimetic Drugs
    Figure 11. Product Picture of Receptors Antagonists
    Figure 12. Product Picture of Others
    Figure 13. Global Genetic Obesity Drug Market Share by Drug Type in 2022 & 2028
    Figure 14. Global Genetic Obesity Drug Market Size by Drug Type (2017-2028) & (US$ Million)
    Figure 15. Global Genetic Obesity Drug Market Share by Drug Type (2017-2028)
    Figure 16. United States Genetic Obesity Drug Market Share by Drug Type in 2022 & 2028
    Figure 17. United States Genetic Obesity Drug Market Size by Drug Type (2017-2028) & (US$ Million)
    Figure 18. United States Genetic Obesity Drug Market Share by Drug Type (2017-2028)
    Figure 19. Product Picture of Hospitals Pharmacy
    Figure 20. Product Picture of Retail Pharmacy
    Figure 21. Product Picture of Online Pharmacy
    Figure 22. Product Picture of Others
    Figure 23. Global Genetic Obesity Drug Market Share by Application in 2022 & 2028
    Figure 24. Global Genetic Obesity Drug Market Size by Application (2017-2028) & (US$ Million)
    Figure 25. Global Genetic Obesity Drug Market Share by Application (2017-2028)
    Figure 26. United States Genetic Obesity Drug Market Share by Application in 2022 & 2028
    Figure 27. United States Genetic Obesity Drug Market Size by Application (2017-2028) & (US$ Million)
    Figure 28. United States Genetic Obesity Drug Market Share by Application (2017-2028)
    Figure 29. North America Genetic Obesity Drug Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 30. United States Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Canada Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. Europe Genetic Obesity Drug Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 33. Germany Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. France Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. U.K. Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Italy Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Russia Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Asia-Pacific Genetic Obesity Drug Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 39. China Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Japan Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. South Korea Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. India Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Australia Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. China Taiwan Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Indonesia Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Thailand Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Malaysia Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Latin America Genetic Obesity Drug Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Mexico Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Brazil Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Argentina Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Genetic Obesity Drug Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Turkey Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. UAE Genetic Obesity Drug Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Pfizer, Inc. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 57. Sanofi. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 58. Tonghua Dongbao Pharmaceutical Co., Ltd. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 59. Biocon. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 60. Adocia Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 61. GlaxoSmithKline Plc. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 62. Novo Nordisk A/S. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 63. Oramed Pharmaceuticals, Inc Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 64. Wockhardt. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 65. Eli Lilly and Company. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 66. Merck & Co., Inc. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 67. Julphar. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 68. Bristol-Myers Squibb Company. Revenue Growth Rate in Genetic Obesity Drug Business (2017-2022)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed

Obesity, a condition in which body fat levels are elevated to extreme extent, is a common disorder. Obesity is a condition caused by the lower levels of the metabolism rate.The current advancement in Genetic Obesity Drugs in rapidly recovering the appetite inhibiting hormone level in the body is anticipated to increase the adoption of Genetic obesity drugs in physicians.

Market Analysis and Insights: Global and United States Genetic Obesity Drug Market

This report focuses on global and United States Genetic Obesity Drug market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Genetic Obesity Drug market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Drug Type, Sibutramine accounting for % of the Genetic Obesity Drug global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospitals Pharmacy was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Genetic Obesity Drug market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Genetic Obesity Drug Scope and Market Size
Genetic Obesity Drug market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Genetic Obesity Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Genetic Obesity Drug market size by players, by Drug Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Drug Type
    Sibutramine
    Orlistat
    Sympathomimetic Drugs
    Receptors Antagonists
    Others

Segment by Application
    Hospitals Pharmacy
    Retail Pharmacy
    Online Pharmacy
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Pfizer, Inc.
    Sanofi.
    Tonghua Dongbao Pharmaceutical Co., Ltd.
    Biocon.
    Adocia
    GlaxoSmithKline Plc.
    Novo Nordisk A/S.
    Oramed Pharmaceuticals, Inc
    Wockhardt.
    Eli Lilly and Company.
    Merck & Co., Inc.
    Julphar.
    Bristol-Myers Squibb Company.